Merck Enters Macular Degeneration Field With Alnylam Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
While Merck already markets glaucoma products (Timoptic, Trusopt, Cosopt), the company does not have an approved AMD therapy. Merck’s first AMD product is expected to reach the clinic in 2005 through an agreement with Alnylam; the companies will split profits of any marketed products in U.S.